Lung Neuroendocrine Neoplasm Clinical Trial
Official title:
A Phase Ib, Open-label Study to Evaluate RAD001 as Monotherapy Treatment in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
The present study is designed to collect safety/tolerability data and explore the efficacy of RAD001 in advanced pulmonary neuroendocrine tumor in Chinese patients.
n/a
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05918302 -
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
|
Phase 3 | |
| Enrolling by invitation |
NCT05064150 -
Neuroendocrine Tumors - Patient Reported Outcomes
|
||
| Active, not recruiting |
NCT03110978 -
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT04893785 -
A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)
|
Phase 2 | |
| Not yet recruiting |
NCT06202066 -
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors
|
Phase 2 | |
| Completed |
NCT02948946 -
Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
|
||
| Recruiting |
NCT04665739 -
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT03600233 -
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
|
Phase 2 |